Osteoporosis Drug Evista Approved To Cut Risk Of Breast Cancer

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

The U.S. Food and Drug Administration approved Evista on Friday for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.